Fenfluramine for Dravet syndrome – first line
NIHR HSRIC
Record ID 32016000425
English
Authors' objectives:
Dravet syndrome is a very rare form of epilepsy that begins in childhood. Prolonged seizures begin in the first year of life and the overall development of children with this disease is often severely affected.
Fenfluramine is a new drug given as a tablet for the treatment of Dravet syndrome. Fenfluramine is being studied to see whether it improves the symptoms of Dravet syndrome and that it is safe to use for children with this disease.
If fenfluramine is licensed for use in the UK, it could be a new treatment option for children with Dravet syndrome and may improve the quality of life of children and their families. At the moment, there are no drugs that treat the underlying causes of Dravet syndrome.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hsric.nihr.ac.uk/topics/fenfluramine-for-dravet-syndrome-first-line/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Seizures
- Epilepsies, Myoclonic
- Fenfluramine
- NAV1.1 Voltage-Gated Sodium Channel
- Spasms, Infantile
- Anticonvulsants
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Centre (NIHR HSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.